Comparing Health Economic Models to Answer Public Health Problems: A Review

Nowadays, decision analysis models are extensively used in solving healthcare problems. Considering the limited resources, the results of these studies will greatly assist policymakers with resource allocation. The purpose of this study is to provide a review of different decision analysis models in healthcare systems and to compare the components used in developing these models in studies addressing cervical cancer prevention. In this comprehensive review on decision analysis models used for cervical cancer prevention, we determined that the major components of the models included costs, outcomes, cycle lengths, discount rate, and perspective. The most commonly used model found in our review was the Markov model; nevertheless, it appears that dynamic models are gaining popularity over recent years. Conclusion: Using decision analysis models and encouraging healthcare policymakers to apply the results of modeling studies will result in saving time and costs, and will facilitate decision making in healthcare issues.

[1]  B. Detournay,et al.  A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer , 2010, International Journal of Public Health.

[2]  A. Chuck Cost-effectiveness of 21 alternative cervical cancer screening strategies. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[3]  Adalsteinn D. Brown,et al.  Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing. , 1999, JAMA.

[4]  J. Salomon,et al.  Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. , 2008, Journal of the National Cancer Institute.

[5]  J. Lew,et al.  Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program. , 2017, The Lancet. Public health.

[6]  L. Cameron,et al.  Risk factors for and prevention of human papillomaviruses (HPV), genital warts and cervical cancer. , 2013, The Journal of infection.

[7]  T. Blakely,et al.  Choosing an epidemiological model structure for the economic evaluation of non-communicable disease public health interventions. , 2016, Population health metrics.

[8]  A. Detsky,et al.  A clinician's guide to cost-effectiveness analysis. , 1990, Annals of internal medicine.

[9]  Chang Ar The cervical smear test in the next millennium. , 1999, Hong Kong medical journal = Xianggang yi xue za zhi.

[10]  S. Wacholder,et al.  Human papillomavirus testing in the prevention of cervical cancer. , 2011, Journal of the National Cancer Institute.

[11]  Karl Claxton,et al.  Assessing Quality in Decision Analytic Cost-Effectiveness Models , 2000, PharmacoEconomics.

[12]  David J. Pannell,et al.  Sensitivity Analysis of Normative Economic Models: Theoretical Framework and Practical Strategies , 1997 .

[13]  M. Sculpher,et al.  Decision Modelling for Health Economic Evaluation , 2006 .

[14]  Mark Schiffman,et al.  The promise of global cervical-cancer prevention. , 2005, The New England journal of medicine.

[15]  Shalini L Kulasingam,et al.  Screening for Cervical Cancer: A Modeling Study for the US Preventive Services Task Force , 2013, Journal of lower genital tract disease.

[16]  P. Tappenden,et al.  Methodological issues in the economic analysis of cancer treatments. , 2006, European journal of cancer.

[17]  J R Beck,et al.  Markov Models in Medical Decision Making , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.

[18]  T. Wright,et al.  Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. , 2005, Journal of the National Cancer Institute.

[19]  G. Sanders,et al.  Decision science and cervical cancer , 2003, Cancer.

[20]  M. García-Molina,et al.  Cost-effectiveness of conventional cytology and HPV DNA testing for cervical cancer screening in Colombia. , 2008, Salud publica de Mexico.

[21]  J. Chahoud,et al.  Wealth, Health Expenditure, and Cancer: A National Perspective. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

[22]  M. Jit,et al.  Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study. , 2014, Vaccine.

[23]  M. Jit,et al.  Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model , 2015, BMJ : British Medical Journal.

[24]  Bernhard Gibis,et al.  The German cervical cancer screening model: development and validation of a decision-analytic model for cervical cancer screening in Germany. , 2006, European journal of public health.

[25]  I. Morhason-Bello,et al.  Modeling optimal cervical cancer prevention strategies in Nigeria , 2014, BMC Cancer.

[26]  N. Muñoz,et al.  Human papillomavirus and cancer: the epidemiological evidence. , 2000, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[27]  E. Weiderpass,et al.  A systematic review of economic aspects of cervical cancer screening strategies worldwide: discrepancy between economic analysis and policymaking. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[28]  Y. Qiao,et al.  Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study , 2011, BMC Cancer.

[29]  Mark Jit,et al.  Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. , 2014, The Lancet. Global health.

[30]  Karen M Kuntz,et al.  Multiparameter calibration of a natural history model of cervical cancer. , 2007, American journal of epidemiology.

[31]  Jane J. Kim,et al.  Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway , 2012, British Journal of Cancer.

[32]  K. Howard,et al.  Cervical cancer screening in Australia: modelled evaluation of the impact of changing the recommended interval from two to three years , 2010, BMC public health.

[33]  Douglas K Owens,et al.  Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials , 1996, The Lancet.

[34]  Paul C Langley Modeling for health care and other policy decisions: uses, roles, and validity. , 2002, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[35]  J. Habbema,et al.  Cost-effectiveness of cervical cancer screening: comparison of screening policies. , 2002, Journal of the National Cancer Institute.

[36]  Y. Taketani,et al.  Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost‐effectiveness analysis , 2012, BJOG : an international journal of obstetrics and gynaecology.

[37]  W. Lawrence,et al.  Benefits and costs of using HPV testing to screen for cervical cancer. , 2002, JAMA.

[38]  Thomas Faunce,et al.  Decision-analytical modelling in health-care economic evaluations , 2008, The European Journal of Health Economics.

[39]  Mark S Roberts,et al.  Simulation and critical care modeling , 2004, Current opinion in critical care.

[40]  M. Shanahan,et al.  The cost‐effectiveness of cervical screening in Australia: what is the impact of screening at different intervals or over a different age range? , 2008, Australian and New Zealand journal of public health.

[41]  Jeremy D Goldhaber-Fiebert,et al.  Chapter 18: Public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling. , 2006, Vaccine.

[42]  S. Goldie,et al.  Mathematical models of cervical cancer prevention in Latin America and the Caribbean. , 2008, Vaccine.

[43]  S. You,et al.  Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system , 2010, British Journal of Cancer.

[44]  De Kok Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings : cost effectiveness analysis based on a Dutch microsimulation model , 2017 .

[45]  S. Kulasingam,et al.  Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis , 2009, BMC medicine.

[46]  J. Peto,et al.  The cervical cancer epidemic that screening has prevented in the UK , 2004, The Lancet.

[47]  Tze-Yun Leong,et al.  Multiple Perspective Dynamic Decision Making , 1998, Artif. Intell..

[48]  Robert L Harrison,et al.  Introduction To Monte Carlo Simulation. , 2010, AIP conference proceedings.

[49]  Stavros Petrou,et al.  Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting , 2011, BMJ : British Medical Journal.

[50]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[51]  V Beral,et al.  The predicted effect of changes in cervical screening practice in the UK: results from a modelling study , 2004, British Journal of Cancer.

[52]  A. Farnsworth Screening for the Prevention of Cervical Cancer in the Era of Human Papillomavirus Vaccination: An Australian Perspective , 2011, Acta Cytologica.

[53]  Jonathan Karnon,et al.  Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation. , 2003, Health economics.

[54]  E. Weiderpass,et al.  Priority Setting for Improvement of Cervical Cancer Prevention in Iran. , 2015, International journal of health policy and management.

[55]  Sue J Goldie,et al.  Cost-effectiveness of cervical-cancer screening in five developing countries. , 2005, The New England journal of medicine.

[56]  Graham A. Colditz,et al.  Cost-effectiveness of screening for colorectal cancer in the general population. , 2000, JAMA.

[57]  J. Dillner,et al.  Cost‐effectiveness of primary cytology and HPV DNA cervical screening , 2008, International journal of cancer.

[58]  S Gallivan,et al.  Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK , 2006, British Journal of Cancer.

[59]  Y. Qiao,et al.  Cost‐effectiveness analysis of cervical cancer prevention based on a rapid human papillomavirus screening test in a high‐risk region of China , 2010, International journal of cancer.

[60]  B E Hillner,et al.  Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. , 1991, The New England journal of medicine.

[61]  T. Wright,et al.  Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. , 2001, JAMA.

[62]  J. Habbema,et al.  Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the (cost-)effectiveness. , 1997, British Journal of Cancer.

[63]  Evan R. Myers,et al.  Cost-Effectiveness Analysis of Liquid-Based Cytology and Human Papillomavirus Testing in Cervical Cancer Screening , 2006, Obstetrics and gynecology.

[64]  W. Lawrence,et al.  Costs and benefits of different strategies to screen for cervical cancer in less-developed countries. , 2002, Journal of the National Cancer Institute.

[65]  T. Wright,et al.  Cost-Effectiveness of Human Papillomavirus DNA Testing for Cervical Cancer Screening in Women Aged 30 Years or More , 2004, Obstetrics and gynecology.

[66]  C. Mathers,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .

[67]  G. Dreyer,et al.  Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa. , 2009, Gynecologic oncology.

[68]  K. Goodman,et al.  Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening. , 2010, Gynecologic oncology.

[69]  J. Salomon,et al.  Cost-effectiveness of Rotavirus vaccination in Vietnam , 2009, BMC public health.

[70]  John Eng,et al.  Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. , 2003, JAMA.

[71]  Sally C. Brailsford,et al.  A comparison of discrete event simulation and system dynamics for modelling health care systems , 2001 .

[72]  T. Chen,et al.  Efficacy and cost-effectiveness of nationwide cervical cancer screening in Taiwan. , 2006, Journal of medical screening.

[73]  A. Mrhar,et al.  Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia. , 2010, European journal of public health.

[74]  A. Nahvijou,et al.  Cost-Effectiveness of Different Cervical Screening Strategies in Islamic Republic of Iran: A Middle-Income Country with a Low Incidence Rate of Cervical Cancer , 2016, PloS one.

[75]  E. Myers,et al.  Costs and Effectiveness of Alternative Strategies for Cervical Cancer Screening in Military Beneficiaries , 2002, Obstetrics and gynecology.

[76]  J. Berkhof,et al.  The health and economic effects of HPV DNA screening in The Netherlands , 2010, International journal of cancer.